Literature DB >> 19155727

Dermatomyositis: a clinicopathological study of 40 patients.

Edward S Smith1, James R Hallman, Amena M DeLuca, Gary Goldenberg, Joseph L Jorizzo, Omar P Sangueza.   

Abstract

The histopathology of cutaneous lesions of dermatomyositis (DM) may be indistinguishable from acute cutaneous lesions of systemic lupus erythematosus (SLE). Misreported or incomplete clinical information may result in a clinicopathologic discrepancy and a delay in making a correct diagnosis of DM. The aim of this study was to systematically characterize the histopathologic findings of cutaneous lesions of DM and to determine if skin biopsy specimens of DM and SLE could be distinguished by light microscopic examination. Biopsies from 40 patients diagnosed with DM at the Wake Forest University School of Medicine from 1994 to 1999 were reviewed. The histological features by light microscopy were graded in a systematic fashion. We then assessed whether the cutaneous pathological changes of DM could be distinguished from those of SLE. Ten biopsy specimens each of DM and SLE (matched for anatomical site and lesion morphology) were randomized. Histological grading was performed in a blinded fashion, as was a histopathologic diagnosis (DM versus SLE). The most consistent histological findings of DM included increased dermal mucin, vacuolar alteration of the basal cell layer, and mild-to-moderate mononuclear cell inflammatory infiltrates. Our results show that the histological grading of SLE skin biopsies was nearly identical to that of DM. The correct histopathologic diagnosis of DM or SLE was made in 11 of the 20 skin biopsies without clinical information. Despite the limitations of our small sample size, these findings suggest that acute cutaneous lesions of SLE cannot be distinguished from DM. Clinicopathologic correlation is important for making a diagnosis of DM or SLE.

Entities:  

Mesh:

Year:  2009        PMID: 19155727     DOI: 10.1097/DAD.0b013e31818520e1

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  9 in total

1.  Dermatomyositis as a paraneoplastic phenomenon in ovarian cancer.

Authors:  Ilyas Arshad; Desmond Barton
Journal:  BMJ Case Rep       Date:  2016-07-08

2.  Dermatomyositis and malignancy.

Authors:  Tina Hu; Ophir Vinik
Journal:  Can Fam Physician       Date:  2019-06       Impact factor: 3.275

3.  Cutaneous manifestations of dermatomyositis and their management.

Authors:  Jeffrey P Callen
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 4.  Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.

Authors:  Nicole M Fett; David Fiorentino; Victoria P Werth
Journal:  Dermatol Clin       Date:  2016-07       Impact factor: 3.478

Review 5.  Rheumatic manifestations of skin disease.

Authors:  Jennie T Clarke; Victoria P Werth
Journal:  Curr Opin Rheumatol       Date:  2010-01       Impact factor: 5.006

6.  Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.

Authors:  Adam S Nabatian; Muhammad M Bashir; Maria Wysocka; Meena Sharma; Victoria P Werth
Journal:  Arthritis Res Ther       Date:  2012-01-04       Impact factor: 5.156

7.  Joint pain with violaceous papules and plaques.

Authors:  Jeena K Sandhu; Anna Chacon; Alexandra D Haden
Journal:  JAAD Case Rep       Date:  2019-05-08

8.  A novel model of dermatomyositis induced by membrane antigen and calciphylaxis in rats.

Authors:  Xin Zhao; Lingyu Li; Shasha Ge; Jinyu Liu; Shuang Li; Hongya Wang; Dayong Cai
Journal:  Biomed Rep       Date:  2022-02-24

9.  Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery.

Authors:  Alan Christie; Neil McKay; Fiona Nussey
Journal:  Gynecol Oncol Case Rep       Date:  2013-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.